Sanofi Rationalizes Its Vaccine Portfolio

Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including its related contract with the Center for Disease Control (CDC). In 2016, Sanofi generated $5.04 billion in net sales from its vaccine products. Its influenza vaccine unit was the second largest contributor to this total, accounting for $1.7 billion in net sales that year, a record year for Sanofi’s influenza campaign. Sanofi Pasteur, the business... Read More »